Antibody Information

General Information of This Antibody
Antibody ID
ANI0FLHRJ
Antibody Name
Fully human anti-CDH6 HKT-288 mAb
Antibody Type
Monoclonal antibody (mAb)
Antigen Name
Cadherin-6 (CDH6)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HKT-288 [Terminated in phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Advanced (metastatic or locally advanced) serous epithelial ovarian, serous fallopian tubal or serous primary peritoneal cancer or advanced clear cell or papillary renal cell carcinoma (RCC), who had received or were intolerant to all therapies known to confer clinical benefit for their disease and Eastern Cooperative Oncology Group (ECOG) performance status 2.

   Click to Show/Hide
Administration Dosage
HKT288 was administered intravenously (IV) every 3 weeks until patients experienced unacceptable toxicity or progressive disease (PD). The starting dose of 0.30 mg/kg was determined based on the highest nonseverely toxic dose in monkeys, which was 2 mg/kg IV weekly.
Related Clinical Trial
NCT Number NCT02947152  Clinical Status Phase 1
Clinical Description
A phase 1, multicenter, open-label dose escalation and expansion study of HKT288, administered intravenously in adult patients with advanced solid tumors, including epithelial ovarian cancer and renal cell carcinoma.
Primary Endpoint
The best overall response on the 0.30 mg/kg cohort in patients with measurable disease was RECIST v1.1 stable disease in 3 patients and PD in 2 patients.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with advanced solid tumors, including epithelial ovarian cancer and renal cell carcinoma.
Administration Dosage
Cadherin-6-targeting ADC iv at dose of 0.30, 0.75 mg/kg.
Related Clinical Trial
NCT Number NCT02947152  Clinical Status Phase 1
Clinical Description
A phase 1, multicenter, open-label dose escalation and expansion study of HKT288, administered intravenously in adult patients with advanced solid tumors, including epithelial ovarian cancer and renal cell carcinoma.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.00% (Day 45) High CDH6 expression (CDH6+++)
Method Description
CDH6-sulfo-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 45) High CDH6 expression (CDH6+++)
Method Description
CDH6-sulfo-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
References
Ref 1 A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncol Res Treat. 2021;44(10):547-556.
Ref 2 A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Ref 3 Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. Cancer Discov. 2017 Sep;7(9):1030-1045.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.